Skip to content

Motor Response after Dorsal Root Ganglion Stimulation: A pilot study of 10 patients with Motor Complete Paraplegia.

Motor Response after Dorsal Root Ganglion Stimulation: A pilot study of 10 patients with Motor Complete Paraplegia. - DRG Motor Response Study

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON47916
Enrollment
10
Registered
2018-09-07
Start date
2018-06-04
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Paraplegia Spinal Cord Injury

Interventions

All ten patients in this pilot study will receive a surgical placement of a DRG stimulator. In addition, they will undergo EMG measurements and other tests (see section on primary and secondary outc
Dorsal Root Ganglion
Electrical Stimulation
Motor Response
Paraplegia

Sponsors

Erasmus MC, Universitair Medisch Centrum Rotterdam
Lead Sponsor

Eligibility

Age
18 Years to 64 Years

Inclusion criteria

Inclusion criteria: - Paraplegia caused by trauma >2 years prior to inclusion - Grade A or B neurological deficit on the ASIA Impairment scale - Age >17 years - Any Wounds (e.g. decubitus)

Exclusion criteria

Exclusion criteria: - Depression or an anxiety disorder - Pregnancy - Life expectancy

Design outcomes

Primary

MeasureTime frame
The aim of this case series is to investigate if DRG stimulation can evoke motor responses in the lower extremities in patients with motor complete spinal cord injury.

Secondary

MeasureTime frame
In addition to motor response, we will try to investigate the following secondary objectives: - Weight-bearing ability (Non-assisted standing) - Assisted Standing - Muscle Strength (measured using a MicroFet 2 dynamometer and the MRC scale for muscle strength) - Voluntary movements - Patient Expectations of experimental treatment - Pain experience during stimulation

Countries

The Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)